Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations

[1]  G. Zaman,et al.  A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells , 2021, Oncology research.

[2]  Z. Tothova,et al.  The Role of PI3K/AKT and MAPK Signaling Pathways in Erythropoietin Signalization , 2021, International journal of molecular sciences.

[3]  Rosalin Mishra,et al.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects , 2021, International journal of molecular sciences.

[4]  Yang Gao,et al.  Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells , 2021, International journal of biological sciences.

[5]  H. Reikvam,et al.  The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells , 2020, International journal of molecular sciences.

[6]  H. Keun,et al.  Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells , 2020, British Journal of Cancer.

[7]  Naga Rajiv Lakkaniga,et al.  FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second‐generation arylidene indanone scaffold , 2020, Biotechnology and applied biochemistry.

[8]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[9]  Herman Yeger,et al.  Combination therapy in combating cancer , 2017, Oncotarget.

[10]  Y. Lai,et al.  MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine , 2015, Medical Oncology.

[11]  G. Vassiliou,et al.  Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? , 2014, Disease Models & Mechanisms.

[12]  D. Kaden,et al.  Conference Organizers: Abstract Review Committee: Programs Subcommittee: Acknowledgement of Support , 2022 .

[13]  M. Robson,et al.  Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors , 2014, Cancer science.

[14]  D. Knighton,et al.  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. , 2010, ACS medicinal chemistry letters.

[15]  K. Mahajan,et al.  PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics , 2012, Journal of cellular physiology.

[16]  D. Gerber,et al.  Targeting the PI3K pathway for cancer therapy. , 2012, Future medicinal chemistry.

[17]  C. Arteaga,et al.  Will PI3K pathway inhibitors be effective as single agents in patients with cancer? , 2011, Oncotarget.

[18]  C. Kumar,et al.  Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. , 2011, Genes & cancer.

[19]  B. Brandhuber,et al.  Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.

[20]  Patrick Mayeux,et al.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia , 2010, Haematologica.

[21]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[22]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[23]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .